Side-by-side · Research reference

TirzepatidevsTriptorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BFDA-ApprovedHUMAN-REVIEWED16/64 cited

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

Triptorelin

GnRH Agonist · FDA-Approved

3.75–22.5 mgDepot dose rangeYee 2025 Chen 2024

<50 ng/dLTestosterone target

1–6 monthsDepot durationYee 2025 Chen 2024

IM · Depot Injection · Monthly to 6-MonthlyYee 2025

01Mechanism of Action

Parameter

Tirzepatide

Triptorelin

Primary target

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pituitary GnRH receptorsUnknown 2012

Pathway

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression

Downstream effect

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression

Origin

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability

Antibody development

—

02Dosage Protocols

Parameter

Tirzepatide

Triptorelin

Standard dose (T2D)

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

—

Standard dose (weight)

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

—

Titration schedule

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Multiple Phase 3 RCTs · FDA-approved 1999

Duration

Indefinite for chronic indication

—

Reconstitution

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

—

Timing

Once weekly, any time of day

—

Half-life

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

—

1-month depot

—

3.75 mg IM

Most common formulation for prostate cancer.

3-month depot

—

11.25 mg IMYee 2025

Reduced injection frequency.

6-month depot

—

22.5 mg IMYee 2025 Chen 2024

Long-acting formulation; improved adherence in real-world use.Yee 2025

Administration route

—

Intramuscular (IM) — gluteal or deltoid

Frequency

—

Every 1, 3, or 6 months per formulation

Indication: Prostate cancer

—

Advanced (metastatic or locally advanced)

Androgen deprivation therapy (ADT) backbone.

Indication: Endometriosis

—

3.75 mg monthly

FDA-approved; typically 6-month course.

Indication: Central precocious puberty

—

Pediatric use (≥2 years)Jia 2025

Weight-based dosing per FDA label.

Duration (prostate cancer)

—

Continuous or intermittent ADT protocolsPreston 2024

Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.

Monitoring

—

Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose

04Side Effects & Safety

Parameter

Tirzepatide

Triptorelin

GI symptoms

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

—

Injection site reaction

Mild erythema, pruritus

—

Pancreatitis risk

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

—

Hypoglycemia

Low as monotherapy; risk with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

Contraindicated

—

Diabetic retinopathy

Rapid glycemic improvement may transiently worsen

—

Initial flare symptoms

—

Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)

Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.

Cardiovascular events

—

MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025 Preston 2024

Hot flashes

—

Very common (>60%); vasomotor instability

Bone loss / Osteoporosis

—

Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025

Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.

Metabolic syndrome

—

Weight gain, insulin resistance, dyslipidemia, diabetes risk

Sexual dysfunction

—

Erectile dysfunction, loss of libido (expected pharmacological effect)Jia 2025

Injection site reactions

—

Pain, erythema, sterile abscess (rare with depot formulations)

Gynecomastia / Breast tenderness

—

Common (10–20%); peripheral aromatization of residual androgens

Fatigue / Mood changes

—

Anemia, depression, cognitive changes reported in long-term ADT

Hepatotoxicity

—

Transient transaminase elevations; clinically apparent liver injury rare

Racial differences (ADT)

—

Black veterans show higher CV event rates vs White veterans on GnRH agonists

Absolute Contraindications

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Triptorelin

·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
·Pregnancy (Category X)

Relative Contraindications

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

Triptorelin

·Active cardiovascular disease — consider GnRH antagonist alternative
·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
·Severe urinary obstruction — may worsen during flare
·Osteoporosis or high fracture risk (requires bone-protective therapy)

05Administration Protocol

Parameter

Tirzepatide

Triptorelin

1. Reconstitution / device

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.

3. Timing

Once weekly, same day. Day change allowed if ≥3 days separate doses.

For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.

4. Storage

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.

5. Needle

Pen-supplied. Research vial: 27–31G insulin syringe.

Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.

6. Intermittent ADT protocol (optional)

—

Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.